GlobeImmune
Manufacturing · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1450 Infinite Dr, Louisville, Colorado, ...Phone Number
(303) 625-2700Website
www.globeimmune.comRevenue
$6.2 MillionStock Symbol
GBIMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About GlobeImmune
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical developmentRead more
GlobeImmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GlobeImmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at GlobeImmune
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if GlobeImmune has recently received funding, and reach out quickly before it becomes old news!
GlobeImmune, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when GlobeImmune launches new products
Website visits: Recent activity has been detected on your website
Check out if GlobeImmune is spiking on competitors!
Click to see if GlobeImmune had a recent Job posting/layoffs
Earning: See what the market has to say on GlobeImmune recently announced quarterly report
Funding: Get notified immidiatlly once GlobeImmune has new funding data
Recommended Actions
Find VP level buyers at GlobeImmune
Find more new buyers
Compare Similar Companies to GlobeImmune
Compare insights from companies similar to GlobeImmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GlobeImmune is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GlobeImmune is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GlobeImmune.
GlobeImmune financials insights
Gather financial insights about GlobeImmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$15M
GlobeImmune Tech Stack
A closer look at the technologies used by GlobeImmune
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GlobeImmune
Sign Up For FreeTo access detailed company insights
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppre... Read More
